She's an excellent presenter and mercifully devoid of colloquialisms and hyperbole.
Plenty to like about the stable of products and results to date.
Only issue is that she confirmed that there is little of substance regarding trial progress / efficacy expected to be reported before late-2023 or H1-2024, so looks certain that capital will need to be raised prior to this reporting. Big issue as per my posts on the Capital Raise thread, and not addressed in the presentation. To me this uncertainty is the main explanation for such a paltry market cap given the potential of the products ...
Sentiment is "sell" only because I believe that there will be a significantly discounted capital raise providing an opportunity to buy lower.
CHM Price at posting:
6.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)